AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32769625 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive training intervention (8-week duration, combining webinar classes and online computer game training)
Number of subjects: 10
Study 32769625 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive training intervention
Number of subjects: 10
Study 35035842 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Operating Procedure (SOP) for VTE prevention
Number of subjects: 120
Study 35035842 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing (Control Group)
Number of subjects: 120
Study 32061707 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning label
Number of subjects: 1997
Study 32061707 — intervention group
Group type: EXPERIMENTAL
Intervention: Health star rating
Number of subjects: 1997
Study 32061707 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic light labelling
Number of subjects: 1997
Study 32061707 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1997
Study 32061707 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease risk reduction claim
Number of subjects: 1997
Study 32061707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient content claim
Number of subjects: 1997
Study 35114798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure lowering (<130 mm Hg)
Number of subjects: 3019
Study 35114798 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure lowering (130-149 mm Hg)
Number of subjects: 3019
Study 32068571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane sedation
Number of subjects: 100
Study 32068571 — intervention group
Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 100
Study 35851679 — intervention group
Group type: EXPERIMENTAL
Intervention: BCM Diät™ (diet 1)
Number of subjects: 90
Study 35851679 — intervention group
Group type: EXPERIMENTAL
Intervention: Optifast™ (diet 2)
Number of subjects: 90
Study 32027191 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age at delivery ≥32 weeks
Number of subjects: 51
Study 32027191 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based management
Number of subjects: 51
Study 32027191 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of magnesium sulphate
Number of subjects: 51
Study 32027191 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age at diagnosis ≥28 weeks
Number of subjects: 51
Study 32027191 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight ≥1000 g
Number of subjects: 51
Study 33946255 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP treatment with enhanced support from a physiotherapist
Number of subjects: 98
Study 33027156 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mentor mother visits only
Number of subjects: 1275
Study 33027156 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages only
Number of subjects: 1275
Study 33027156 — intervention group
Group type: COMPARATOR
Intervention: Preconception ART initiation
Number of subjects: 1275
Study 33027156 — intervention group
Group type: COMPARATOR
Intervention: Post-conception ART initiation
Number of subjects: 1275
Study 36311525 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) - 1.5 mA, 20 min, 6 sessions in 2 weeks
Number of subjects: 39
Study 36311525 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 39
Study 34506596 — intervention group
Group type: EXPERIMENTAL
Intervention: Equol supplement
Number of subjects: 57
Study 34506596 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study 34748263 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss diet intervention
Number of subjects: 551
Study 33108761 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise programs
Number of subjects: 0
Study 33108761 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33042934 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-time exercise (ZTEx) intervention
Number of subjects: 673
Study 33042934 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy eating information)
Number of subjects: 673
Study 34864830 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness mobile application (Headspace) used daily for at least 6 weeks
Number of subjects: 56
Study 34864830 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no application use)
Number of subjects: 56
Study 32405884 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instrument (PSI)
Number of subjects: 48
Study 32405884 — intervention group
Group type: COMPARATOR
Intervention: Control group (without PSI)
Number of subjects: 48
Study 35847786 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolong Life with Nine Turn Method (PLWNT) Qigong exercise
Number of subjects: 90
Study 35847786 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 90
Study 35847786 — intervention group
Group type: EXPERIMENTAL
Intervention: PLWNT intervention
Number of subjects: 90
Study 35847786 — intervention group
Group type: COMPARATOR
Intervention: CBT intervention
Number of subjects: 90
Study 32090464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal local anaesthetic (IPLA) with ropivacaine instillation followed by a 3-day infusion.
Number of subjects: 60
Study 32090464 — intervention group
Group type: COMPARATOR
Intervention: Placebo group receiving 0.9% saline solution.
Number of subjects: 60
Study 37664793 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study 33909227 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based depression screening
Number of subjects: 88
Study 34187845 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe (GI Genius, Medtronic)
Number of subjects: 660
Study 34187845 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CADe)
Number of subjects: 660
Study 34187845 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe
Number of subjects: 660
Study 34187845 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe (pooled data from AID-1 and AID-2)
Number of subjects: 660
Study 34187845 — intervention group
Group type: COMPARATOR
Intervention: Level of examiner experience
Number of subjects: 660
Study 32479703 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35903847 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-step nutrition intervention
Number of subjects: 78
Study 35903847 — intervention group
Group type: COMPARATOR
Intervention: Routine nutrition management (Control)
Number of subjects: 78
Study 33675342 — intervention group
Group type: EXPERIMENTAL
Intervention: VA-fortified rice (500 µg RAEs/d)
Number of subjects: 70
Study 33675342 — intervention group
Group type: COMPARATOR
Intervention: Unfortified rice
Number of subjects: 70
Study 35882364 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus guided deprexis (TAU-PLUS)
Number of subjects: 69
Study 35882364 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment-as-usual)
Number of subjects: 69
Study 33950370 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional simulation training along with institutional training
Number of subjects: 50
Study 33950370 — intervention group
Group type: COMPARATOR
Intervention: Traditional training only
Number of subjects: 50
Study 35175208 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook group intervention (CAN Quit) designed to promote evidence-based smoking cessation resources
Number of subjects: 0
Study 32785044 — intervention group
Group type: EXPERIMENTAL
Intervention: Be Healthe for your Heart, a web‐based behavioral intervention
Number of subjects: 31
Study 32785044 — intervention group
Group type: COMPARATOR
Intervention: Control, access to the National Heart Foundation website
Number of subjects: 31
Study 36030153 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoglycemia checklist applied preoperatively, intraoperatively, and postoperatively with continuous insulin infusion to maintain blood glucose levels between 80 to 150 mg/dl for 48 hours postoperative
Number of subjects: 0
Study 36030153 — intervention group
Group type: COMPARATOR
Intervention: Routine practice available in the clinic (control group)
Number of subjects: 0
Study 36030153 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 33535212 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate dialysate (CD)
Number of subjects: 0
Study 33535212 — intervention group
Group type: COMPARATOR
Intervention: Acetate dialysate (AD)
Number of subjects: 0
Study 32320729 — intervention group
Group type: COMPARATOR
Intervention: FS (500 ppm F- + 800 ppm Sn2+ - positive control)
Number of subjects: 60
Study 32320729 — intervention group
Group type: EXPERIMENTAL
Intervention: FS + Carbopol (0.1% Carbopol)
Number of subjects: 60
Study 32320729 — intervention group
Group type: COMPARATOR
Intervention: Ultrapure water (negative control)
Number of subjects: 60
Study 35436142 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (20 g)
Number of subjects: 48
Study 35436142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 34359097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 92/22 μg
Number of subjects: 93
Study 34359097 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 400 μg
Number of subjects: 93
Study 32540725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinacurcumin® 80 mg daily
Number of subjects: 30
Study 32540725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34235862 — intervention group
Group type: EXPERIMENTAL
Intervention: TB treatment
Number of subjects: 574
Study 34235862 — intervention group
Group type: COMPARATOR
Intervention: No TB treatment
Number of subjects: 574
Study 33743390 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary rhythm protocol
Number of subjects: 31
Study 33743390 — intervention group
Group type: EXPERIMENTAL
Intervention: Quaternary rhythm protocol
Number of subjects: 31
Study 33220326 — intervention group
Group type: EXPERIMENTAL
Intervention: L-menthol mouthwash
Number of subjects: 22
Study 33220326 — intervention group
Group type: COMPARATOR
Intervention: Control mouthwash
Number of subjects: 22
Study 36192209 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 11
Study 36192209 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC): plasmapheresis/intravenous immunoglobulin
Number of subjects: 11
Study 36192209 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 11
Study 33196921 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-lilotomab satetraxetan
Number of subjects: 16
Study 36460023 — intervention group
Group type: EXPERIMENTAL
Intervention: Free HIV self-test kit (BT group)
Number of subjects: 10111
Study 36460023 — intervention group
Group type: COMPARATOR
Intervention: No free HIV self-test kit (nBT group)
Number of subjects: 10111
Study 35802483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (1.5 μg/kg)
Number of subjects: 34
Study 35802483 — intervention group
Group type: COMPARATOR
Intervention: PO acetaminophen/hydrocodone (0.15 mg/kg)
Number of subjects: 34
Study 32488435 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced pneumatic compression device (APCD) used once per day (instead of prescribed twice per day).
Number of subjects: 49
Study 32488435 — intervention group
Group type: COMPARATOR
Intervention: Lymphedema self-management (standard of care).
Number of subjects: 49
Study 32512262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 108
Study 32512262 — intervention group
Group type: COMPARATOR
Intervention: Maintenance treatment
Number of subjects: 108
Study 35772416 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspend methotrexate group
Number of subjects: 254
Study 35772416 — intervention group
Group type: COMPARATOR
Intervention: Continue methotrexate group
Number of subjects: 254
Study 34468814 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 0
Study 34468814 — intervention group
Group type: COMPARATOR
Intervention: Inorganic salt particles exposure
Number of subjects: 0
Study 34468814 — intervention group
Group type: COMPARATOR
Intervention: HVO exhaust with aftertreatment exposure
Number of subjects: 0
Study 34468814 — intervention group
Group type: COMPARATOR
Intervention: HVO exhaust without aftertreatment exposure
Number of subjects: 0
Study 35287662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethics Quarter (EQ) e-learning intervention
Number of subjects: 95
Study 34758887 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX) induction, n = 20
Number of subjects: 37
Study 34758887 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX) induction, n = 17
Number of subjects: 37
Study 34758887 — intervention group
Group type: COMPARATOR
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 37
Study 36115962 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application (reminder app)
Number of subjects: 53
Study 36115962 — intervention group
Group type: COMPARATOR
Intervention: No mobile application (control group)
Number of subjects: 53
Study 33368358 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Number of subjects: 0
Study 33368358 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 0
Study 33368358 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab
Number of subjects: 0
Study 34787383 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct osteopathic primary care sports medicine intervention (n=18)
Number of subjects: 23
Study 34787383 — intervention group
Group type: COMPARATOR
Intervention: Control group without active intervention (n=19)
Number of subjects: 23
Study 34787383 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall team performance during the intervention season
Number of subjects: 23
Study 35039206 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen with photolyase (SC+P)
Number of subjects: 40
Study 35039206 — intervention group
Group type: COMPARATOR
Intervention: Regular sunscreen (SC)
Number of subjects: 40
Study 35039206 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antioxidants (AOx)
Number of subjects: 40
Study 35039206 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 40
Study 33556442 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C
Number of subjects: 300000
Study 33556442 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-C
Number of subjects: 300000
Study 33556442 — intervention group
Group type: EXPERIMENTAL
Intervention: TGs
Number of subjects: 300000
Study 33556442 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 300000
Study 33556442 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D
Number of subjects: 300000
Study 33556442 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP
Number of subjects: 300000
Study 33556442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid trait genetic variants
Number of subjects: 300000
Study 32209712 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating mesh nebulizer
Number of subjects: 217
Study 32209712 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer
Number of subjects: 217
Study 35066706 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages
Number of subjects: 25
Study 35066706 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app
Number of subjects: 25
Study 35066706 — intervention group
Group type: COMPARATOR
Intervention: Paper diaries
Number of subjects: 25
Study 32434773 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised patient approach
Number of subjects: 52
Study 33970846 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon alpha (rhIFN‐α) nasal drops for one month in the low-risk group
Number of subjects: 2944
Study 33970846 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon alpha (rhIFN‐α) nasal drops coupled with thymosin‐α1 in the high-risk group
Number of subjects: 2944
Study 33089293 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss bone powder with Heal-All Oral repair membrane
Number of subjects: 26
Study 33089293 — intervention group
Group type: COMPARATOR
Intervention: Bio-Oss collagen
Number of subjects: 26
Study 35326273 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic Coordinated Reset (CR®) Neuromodulation using the T30 neurostimulator with proprietary sound sequence
Number of subjects: 100
Study 35326273 — intervention group
Group type: COMPARATOR
Intervention: Placebo algorithm of the T30 neurostimulator
Number of subjects: 100
Study 35260261 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient experience story (bad story)
Number of subjects: 809
Study 35260261 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient experience story (neutral story)
Number of subjects: 809
Study 35260261 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient experience story (good story)
Number of subjects: 809
Study 35260261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-rater reliability
Number of subjects: 809
Study 35260261 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient experience story (bad/neutral)
Number of subjects: 809
Study 33630072 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 594
Study 33630072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study 32361265 — intervention group
Group type: EXPERIMENTAL
Intervention: Necuparanib (5 mg/kg subcutaneous injection once daily)
Number of subjects: 110
Study 32361265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous injection once daily)
Number of subjects: 110
Study 32361265 — intervention group
Group type: EXPERIMENTAL
Intervention: Necuparanib
Number of subjects: 110
Study 33668849 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day algal docosahexaenoic acid (DHA)
Number of subjects: 957
Study 33668849 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two microencapsulated soy and corn oil tablets)
Number of subjects: 957
Study 32379216 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved Gengnianchun (I-GNC)
Number of subjects: 98
Study 32379216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 36477779 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training (drinking water multiple times and retaining urine for three days)
Number of subjects: 150
Study 36477779 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular drinking and urination habits without special instructions)
Number of subjects: 150
Study 32336696 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin + Probucol + Cilostazol
Number of subjects: 281
Study 32336696 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin + Probucol
Number of subjects: 281
Study 32336696 — intervention group
Group type: COMPARATOR
Intervention: Statin alone
Number of subjects: 281
Study 35176038 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet with intravenous vitamin D receptor activator (low dose < 1.5 μg)
Number of subjects: 253
Study 35176038 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet with intravenous vitamin D receptor activator (high dose ≥ 1.5 μg)
Number of subjects: 253
Study 35176038 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet with intravenous vitamin D receptor activator (all groups)
Number of subjects: 253
Study 34721802 — intervention group
Group type: EXPERIMENTAL
Intervention: General Medicine (GM) rotation
Number of subjects: 386
Study 34721802 — intervention group
Group type: COMPARATOR
Intervention: Intensive Care Unit (ICU) rotation
Number of subjects: 386
Study 32964624 — intervention group
Group type: EXPERIMENTAL
Intervention: FA‐treatment with in-session exposure (FA‐ISE)
Number of subjects: 90
Study 32964624 — intervention group
Group type: COMPARATOR
Intervention: FA‐treatment without in-session exposure (FA)
Number of subjects: 90
Study 35728577 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + L‐PRF
Number of subjects: 30
Study 35728577 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + A‐PRF
Number of subjects: 30
Study 32124801 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP genes RLN2 (rs4742076, rs3758239)
Number of subjects: 100
Study 32124801 — intervention group
Group type: EXPERIMENTAL
Intervention: IL4 (rs2243250)
Number of subjects: 100
Study 32124801 — intervention group
Group type: EXPERIMENTAL
Intervention: IL10 (rs1800872)
Number of subjects: 100
Study 32124801 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR2 gene expression
Number of subjects: 100
Study 32124801 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR4 gene expression
Number of subjects: 100
Study 32124801 — intervention group
Group type: EXPERIMENTAL
Intervention: FoxP3 expression
Number of subjects: 100
Study 35300258 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific training based on motor relearning program (MRP)
Number of subjects: 66
Study 35300258 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy program (CPT)
Number of subjects: 66
Study 32199708 — intervention group
Group type: COMPARATOR
Intervention: Fluid restriction alone (FR)
Number of subjects: 92
Study 32199708 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid restriction and furosemide (FR+FM)
Number of subjects: 92
Study 32199708 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid restriction, furosemide, and NaCl (FR+FM+NaCl)
Number of subjects: 92
Study 34357505 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Energy Diet (VLED) for 2 months
Number of subjects: 42
Study 34357505 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss maintenance diets for 10 months
Number of subjects: 42
Study 32503657 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir 1600mg each dose, twice a day on the 1st day; 600mg each dose, twice a day from the 2nd to the 7th day, for a maximum of 14 days plus routine treatment for COVID-19.
Number of subjects: 210
Study 32503657 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment for patients with COVID-19, including oxygen therapy and drugs that reduce phlegm and relieve cough.
Number of subjects: 210
Study 36281496 — intervention group
Group type: EXPERIMENTAL
Intervention: ORMD‐0801 8 mg BID
Number of subjects: 373